Overview

ACY-6 Oral Administration of Acyline

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
In this study, we propose oral dosing of GIPET enhanced oral acyline (MER-104) to determine if this potentially useful compound is safe and effective at suppression of gonadotropins after oral dosing in man. Hypothesis: A single dose of Acyline will suppress gonadotropins, and testosterone, estradiol and dihydrotestosterone (DHT) for 24 hours in man, and the magnitude and duration of the suppression will increase with increasing doses of Acyline.
Phase:
Phase 1
Details
Lead Sponsor:
University of Washington
Collaborator:
Merrion Pharmaceuticals, LLC
Treatments:
Acyline